U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07384884) titled 'Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas' on Aug. 11, 2025.
Brief Summary: Butterfly glioblastomas (bGBM), defined as tumours crossing the midline to involve hemispheres bilaterally, have a dismal prognosis with a median survival of 3.3-6 months and only 9% of patients with bGBM survive 2-years. These figures put bGBM in the worst end of the spectrum of GBM prognosis, significantly inferior to the survival figures quoted in the literature with standard of care - 14.6 months - particularly when 5-aminolevulinic acid is used as surgical adjuvant - 17.47 months.
Despite the poor outcome of this disease...